...
首页> 外文期刊>Molecular cancer therapeutics >Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer
【24h】

Targeting MUC1-C Inhibits TWIST1 Signaling in Triple-Negative Breast Cancer

机译:靶向MUC1-C抑制三重阴性乳腺癌中的Twist1信号传导

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The oncogenic MUC1-C protein and the TWIST1 epithelial-mesenchymal transition transcription factor (EMT-TF) are aberrantly expressed in triple-negative breast cancer (TNBC) cells. However, there is no known association between MUC1-C and TWIST1 in TNBC or other cancer cells. Here, we show that MUC1-C activates STAT3, and that MUC1-C and pSTAT3 drive induction of the TWIST1 gene. In turn, MUC1-C binds directly to TWIST1, and MUC1-C/TWIST1 complexes activate MUC1-C expression in an autoinductive circuit. The functional significance of the MUC1-C/TWIST1 circuit is supported by the demonstration that this pathway is sufficient for driving (i) the EMT-TFs, ZEB1 and SNAIL (ii) multiple genes in the EMT program as determined by RNA-seq, and (iii) the capacity for cell invasion. We also demonstrate that the MUC1-C/TWIST1 circuit drives (i) expression of the stem cell markers SOX2, BMI1, ALDI1, and CD44, (ii) self-renewal capacity, and (iii) tumorigenicity. In concert with these results, we show that MUC1-C and TWIST1 also drive EMT and sternness in association with acquired paclitaxel (VEX) resistance. Of potential therapeutic importance, targeting MUC1-C and thereby TWIST1 reverses the PTX refractory phenotype as evidenced by synergistic activity with PTX against drug-resistant cells. These findings uncover a master role for MUC1-C in driving the induction of TWIST1, EMT, sternness, and drug resistance, and support MUC1-C as a highly attractive target for inhibiting TNBC plasticity and progression.
机译:致癌癌蛋白和Twist1上皮 - 间充质转换转录因子(EMT-TF)在三阴性乳腺癌(TNBC)细胞中异常表达。然而,在TNBC或其他癌细胞中的MUC1-C和Twist1之间没有已知关联。在这里,我们显示MUC1-C激活STAT3,并且该MUC1-C和PSTAT3驱动器诱导Twist1基因。反过来,MUC1-C直接绑定到TWICK1,MUC1-C / TWICK1复合物激活在自动诱导电路中的MUC1-C表达式。 MUC1-C / TWICK1电路的功能意义由演示支持,即该途径足以驱动(i)由RNA-SEQ确定的EMT程序中的EMT-TFS,ZEB1和蜗牛(II)多基因, (iii)细胞入侵能力。我们还证明了MUC1-C / TWICK1电路驱动器(I)干细胞标记SOX2,BMI1,ALDI1和CD44,(II)自我更新能力和(III)致瘤性的表达。在音乐会与这些结果中,我们表明MUC1-C和TWICK1还驱动EMT和粗糙度与获得的PACLITAXEL(VEX)电阻相关联。潜在的治疗性重要性,靶向MUC1-C,从而扭转1反转PTX耐火表型,其通过与耐药细胞的PTX协同活性证明。这些发现发现MUC1-C在驱动Twort1,EMT,静脉内和耐药性和耐药性诱导时揭示了MUC1-C的母版作用,以及支持MUC1-C作为抑制TNBC可塑性和进展的高度吸引力的靶标。

著录项

  • 来源
    《Molecular cancer therapeutics》 |2019年第10期|共11页
  • 作者单位

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

    Harvard Med Sch Dana Farber Canc Inst 450 Brookline Ave DANA 830 Boston MA 02215 USA;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号